Metabolism - Clinical and Experimental
Volume 53, Issue 10 , Pages 1322-1330 , October 2004

Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3β on a muscle-specific promoter

  • Nigel J. Pearce

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Nigel J. Pearce, GlaxoSmithKline, New Fontiers Science Park-South, Third Avenue, Harlow CM19 5AW, UK
    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Jonathan R.S. Arch

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • John C. Clapham

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Matthew P. Coghlan

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Stacey L. Corcoran

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Carolyn A. Lister

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Andrea Llano

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Gary B. Moore

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Gregory J. Murphy

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Stephen A. Smith

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Colleen M. Taylor

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • John W. Yates

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Alastair D. Morrison

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Alexander J. Harper

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Lynne Roxbee-Cox

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Alejandro Abuin

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Ed Wargent

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK
    • ,
  • Julie C. Holder

      Affiliations

    • Departments of Vascular Biology and Comparative Genomics, GlaxoSmithKline, Harlow, UK; and the Clore Laboratory, University of Buckingham, Buckingham, UK

Received 26 November 2003 ,Accepted 8 May 2004.

References 

  1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318–368
  2. Rothman DL, Shulman RG, Shulman GI. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate (Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus). J Clin Invest. 1992;89:1069–1075
  3. Cohen P. Muscle glycogen synthase. In:  Boyer P,  Krebs E editor. The Enzymes. New York, NY: Academic Press; 1986;p. 461–497
  4. Nikoulina SE, Ciaraldi TP, Mudaliar S, et al.  Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes. 2000;49:263–271
  5. Cline GW, Petersen KF, Krssak M, et al.  Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med. 1999;341:240–246
  6. Chase JR, Rothman DL, Shulman RG. Flux control in the rat gastrocnemius glycogen synthesis pathway by in vivo 13C/31P NMR spectroscopy. Am J Physiol. 2001;280:E598–E607
  7. Murphy E, Hellerstein M. Is in vivo nuclear magnetic resonance spectroscopy currently a quantitive method for whole-body carbohydrate metabolism?. Nutr Rev. 2000;58:304–314
  8. Ortmeyer HK. In vivo insulin regulation of skeletal muscle glycogen synthase in calorie-restricted and in ad libitum-fed rhesus monkeys. J Nutr. 2001;131:907S–912S
  9. Chang PY, Jenson J, Printz RL, et al.  Overexpression of hexokinase II in transgenic mice. J Biol Chem. 1996;271:14834–14839
  10. Manchester J, Skurat AV, Roach P, et al.  Increased glycogen accumulation in transgenic mice overexpressing glycogen synthase in skeletal muscle. Proc Natl Acad Sci USA. 1996;93:10707–10711
  11. Ren JM, Marshall BA, Mueckler MM, et al.  Overexpression of Glut4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. J Clin Invest. 1995;95:429–432
  12. Gibbs EM, Stock JL, McCoid SC, et al.  Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J Clin Invest. 1995;95:1512–1518
  13. Brozinick JT, Yaspelkis BB, Wilson CM, et al.  Glucose transport and GLUT4 protein distribution in skeletal muscle of GLUT4 transgenic mice. Biochem J. 1996;313:133–140
  14. Perriot LM, Kono T, Whitesell RR, et al.  Glucose uptake and metabolism by cultured human skeletal muscle cells (Rate limiting steps). Am J Physiol. 2001;281:E72–E80
  15. Lawrence JC, Roach P. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes. 1997;46:541–547
  16. Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci USA. 1997;94:9660–9664
  17. Welsh GI, Wilson C, Proud CG. GSK3 (A SHAGGY frog story). Trends Cell Biol. 1996;6:274–279
  18. Schmitz-Peiffer C, Whitehead J. IRS-1 regulation in health and disease. Life. 2003;55:367–374
  19. Hogan B, Beddington R, Constantini F, et al.  Manipulating the Mouse Embryo (A Laboratory Manual). (ed 2). Cold Spring Harbor, NY: Cold Spring Harbor Press; 1994;
  20. Moore GB, Himms-Hagen J, Harper ME, et al.  Overexpression of UCP-3 in skeletal muscle of mice results in increased expression of mitochondrial thioesterase mRNA. Biochem Biophys Res Commun. 2001;283:785–790
  21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254
  22. Coghlan MP, Culbert AA, Cross DAE, et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000;7:793–803
  23. Chan TM, Exton JH. A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem. 1976;71:96–105
  24. Passonneau JV, Lauderdale VR. A comparison of three methods of glycogen measurement in tissues. Anal Biochem. 1974;60:405–412
  25. Young PW, Cawthorne MA, Coyle PJ, et al.  Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes. 1995;44:1087–1092
  26. Ohlsson C, Hellberg N, Parini P, et al.  Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun. 2000;278:640–645
  27. Garofalo RS, Orena SJ, Schachter JB: Transgenic expression of glycogen synthase kinase 3 in muscle. Patent EP 1 321 033 A1. 2003, Europe, 6-12-2002
  28. Bruning JC, Winnay J, Bonner-Weir S, et al.  Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell. 1997;88:561–572
  29. Kido Y, Burks DJ, Withers D, et al.  Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest. 2000;105:199–205
  30. Thomas MK, Devon ON, Lee JH, et al.  Development of diabetes mellitus in aging transgenic mice following suppression of pancreatic homeoprotein IDX-1. J Clin Invest. 2001;108:319–329
  31. Hevener A, Reichart D, Janez A, et al.  Female rats do not exhibit free fatty acid-induced insulin resistance. Diabetes. 2002;51:1907–1912
  32. Picton C, Aitken A, Bilham T, et al.  Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle. Organisation of the seven sites in the polypeptide chain. Eur J Biochem. 1982;124:37–45
  33. Thorburn AW, Gumbiner B, Bulacan F, et al.  Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest. 1990;85:522–529
  34. Damsbo P, Vaag A, Hother-Nielsen O, et al.  Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1991;34:239–245
  35. Wojtaszewski JFP, Hansen BF, Gade J, et al.  Insulin signaling and insulin sensitivity after exercise in human skeletal muscle. Diabetes. 2000;49:325–331
  36. Kida Y, Espsito-Del Puente A, Bogardus C, et al.  Insulin resistance is associated with reduced fasting and insulin-stimulated glycogen synthase phosphatase activity in human skeletal muscle. J Clin Invest. 1990;85:476–481
  37. Saad M, Araki E, Miralpiex M. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest. 1992;90:1839–1849
  38. Kerouz N, Horsch D, Pons S. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest. 1997;100:3164–3172
  39. Hartley D, Cooper GM. Role of mTOR in the degradation of IRS-1 (Regulation of PP2A activity). J Cell Biochem. 2002;85:304–314
  40. Nikoulina SE, Ciaraldi TP, Mudaliar S, et al.  Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes. 2002;51:2190–2198
  41. Beck-Nielsen H, Vaag A, Damsbo P, et al.  Insulin resistance in skeletal muscles in patients with NIDDM. Diabetes Care. 1992;15:418–429
  42. Watts C, Malthus RS. Liver glycogen synthase in rats with a glycogen-storage disorder (The role of glycogen in the regulation glycogen synthase). Eur J Biochem. 1980;108:73–77
  43. Kim JK, Michael MD, Previs SF, et al.  Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest. 2000;105:1791–1797
  44. Smith DG, Buffet M, Fenwick AE, et al.  3-Anilino-4-arylmaleimides (Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)). Bioorg Med Chem Lett. 2001;11:635–639
  45. Martin WH, Hoover DJ, Armento SJ, et al.  Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci USA. 1998;95:1776–1781
  46. Lochhead PA, Coghlan M, Rice SQ, et al.  Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes. 2001;50:937–946
  47. Cline GW, Johnson K, Regittnig W, et al.  Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes. 2002;51:2903–2910
  48. Tabata I, Schluter J, Gulve EA, et al.  Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. Diabetes. 1994;43:903–907
  49. Henriksen EJ, Kinnick TR, Teachey MK, et al.  Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am J Physiol. 2003;284:E892–E900
  50. Ring B, Johnson K, Henriksen E, et al.  Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003;52:588–595
  51. Witherington J, Bordas V, Garland SL, et al.  5-Aryl-pyrazolo [3,4-b]pyridines (Potent inhibitors of glycogen synthase kinase-3 (GSK-3)). Bioorg Med Chem Lett. 2003;13:1577–1580
  52. Witherington J, Bordas V, Haigh D, et al.  5-Aryl-pyrazolo [3,4-b]pyridazines (Potent inhibitors of glycogen synthase kinase-3 (GSK-3)). Bioorg Med Chem Lett. 2003;13:1581–1584

PII: S0026-0495(04)00239-2

doi: 10.1016/j.metabol.2004.05.008

Metabolism - Clinical and Experimental
Volume 53, Issue 10 , Pages 1322-1330 , October 2004

Article Tools

* Image Usage & Resolution